Pharmacogenomics offers an evidence-based approach to individualizing pharmacotherapy by examining how genetic variation influences drug metabolism, transport, target interactions, efficacy and toxicity. Despite advances in precision medicine, conventional prescribing may result in suboptimal therapeutic responses and preventable adverse drug reactions because of interindividual variability. This review critically examines the biological determinants, clinical applications and translational considerations of pharmacogenomics-guided pharmacotherapy. Relevant literature was explored through PubMed/MEDLINE, Scopus, Web of Science, Embase and the Cochrane Library, supplemented by reference-list screening and relevant clinical practice guidelines. Evidence was narratively synthesized to evaluate clinically actionable gene–drug associations, therapeutic outcomes, implementation strategies and existing research gaps. Applications across cardiovascular medicine, oncology, psychiatry, infectious diseases and pain management demonstrate the potential of genotype-informed drug selection, dose individualization and toxicity prevention. Clinical implementation recommendations from established pharmacogenomic resources provide practical guidance for integrating validated genetic findings into prescribing decisions. However, clinical utility varies across gene–drug pairs and depends on evidence strength, test accessibility, result turnaround time, clinical decision-support systems and healthcare infrastructure. Additional challenges include unequal representation of ancestry groups, economic constraints, inconsistent testing practices and limited evidence for certain associations. Effective integration requires collaboration among healthcare professionals, validated testing approaches, interpretable recommendations and continued evaluation of patient outcomes. Pharmacogenomics-guided pharmacotherapy can support safer and more individualized treatment; nevertheless, broader adoption requires stronger prospective evidence, equitable access and sustainable implementation strategies.
Loading....